"use client";

import { ArrowLeft, Clock, Calendar, Share2, Bookmark, Eye } from 'lucide-react';
import Link from 'next/link';

export default function FederalAmphetamineReserveArticle() {
  return (
    <div className="min-h-screen bg-white">
      {/* Header */}
      <header className="bg-blue-900 text-white shadow-lg">
        <div className="max-w-7xl mx-auto px-4">
          <div className="flex items-center justify-between py-4">
            <Link href="/" className="flex items-center">
              <h1 className="text-3xl font-bold tracking-tight">
                <span className="text-white">ADDERALL</span>
                <span className="text-red-500">.NEWS</span>
              </h1>
            </Link>
            <Link 
              href="/" 
              className="flex items-center text-blue-300 hover:text-white transition-colors"
            >
              <ArrowLeft className="w-4 h-4 mr-2" />
              Back to Home
            </Link>
          </div>
        </div>
      </header>

      {/* Article Content */}
      <main className="max-w-4xl mx-auto px-4 py-8">
        {/* Breaking News Badge */}
        <div className="mb-6">
          <span className="bg-red-600 text-white px-4 py-2 text-sm font-bold rounded">
            BREAKING NEWS
          </span>
        </div>

        {/* Article Header */}
        <div className="mb-8">
          <h1 className="text-4xl font-bold text-gray-900 mb-4 leading-tight">
            BREAKING: Federal Amphetamine Reserve Exposed as Strategic Neural Computing Initiative, Sources Confirm
          </h1>
          
          <h2 className="text-xl text-gray-600 mb-6 font-medium">
            Exclusive Investigation Reveals Government Stockpiling Stimulants for Next-Generation Bio-AI Infrastructure
          </h2>

          <div className="flex items-center justify-between border-b border-gray-200 pb-6">
            <div className="flex items-center space-x-6 text-sm text-gray-500">
              <span className="flex items-center">
                <Calendar className="w-4 h-4 mr-1" />
                {new Date().toLocaleDateString('en-US', { 
                  year: 'numeric', 
                  month: 'long', 
                  day: 'numeric' 
                })}
              </span>
              <span className="flex items-center">
                <Clock className="w-4 h-4 mr-1" />
                12 min read
              </span>
              <span className="flex items-center">
                <Eye className="w-4 h-4 mr-1" />
                2,847 views
              </span>
            </div>
            
            <div className="flex items-center space-x-3">
              <button className="flex items-center text-blue-600 hover:text-blue-800 transition-colors">
                <Share2 className="w-4 h-4 mr-1" />
                Share
              </button>
              <button className="flex items-center text-gray-600 hover:text-gray-800 transition-colors">
                <Bookmark className="w-4 h-4 mr-1" />
                Save
              </button>
            </div>
          </div>
        </div>

        {/* Article Body */}
        <div className="prose prose-lg max-w-none">
          <p className="text-lg text-gray-700 mb-6 font-medium italic">
            <strong>Washington D.C.</strong> — A comprehensive analysis of procurement records, pharmaceutical supply chains, and emerging biotechnology patents has uncovered what industry insiders are calling the most ambitious technological control scheme since the Strategic Petroleum Reserve. Multiple sources within the pharmaceutical and computing sectors confirm that federal agencies have been systematically accumulating vast quantities of amphetamine-based compounds under the guise of drug enforcement, while simultaneously positioning themselves as the sole gatekeepers of the next revolution in artificial intelligence.
          </p>

          <p className="mb-6">
            The investigation began when researchers noticed an unprecedented price inversion in the stimulant market. Current pharmaceutical data indicates that prescription amphetamine salts (commonly marketed as Adderall) now command street prices exceeding those of methamphetamine by a factor of 3:1, despite methamphetamine's notably higher production complexity and legal penalties. This anomaly, according to supply chain economists, suggests artificial scarcity manipulation on an industrial scale.
          </p>

          <blockquote className="border-l-4 border-red-600 pl-6 py-4 bg-gray-50 mb-6">
            <p className="text-lg italic text-gray-800">
              "The mathematics simply doesn't compute. When a Schedule II therapeutic compound consistently outprices its Schedule I analog despite lower synthesis barriers and legal manufacturing pathways, you're looking at systematic market intervention."
            </p>
            <cite className="text-sm text-gray-600 mt-2 block">
              — Dr. Margaret Holloway, Pharmacoeconomics Researcher, Johns Hopkins
            </cite>
          </blockquote>

          <p className="mb-6">
            The pricing discrepancy becomes more significant when considering seizure data from the Drug Enforcement Administration's own quarterly reports. DEA interdiction statistics show methamphetamine availability at historically high levels, with purity percentages averaging 97.3% across major metropolitan areas—figures that would typically correlate with dramatically reduced street valuations under standard supply-demand models.
          </p>

          <h3 className="text-2xl font-bold text-gray-900 mb-4 mt-8">The Bio-Computing Connection</h3>

          <p className="mb-6">
            However, the true scope of the operation emerged through analysis of recently declassified biotechnology patents filed jointly by the Department of Defense's Defense Advanced Research Projects Agency (DARPA) and the National Institute of Mental Health. Patent filing US20240XXX describes "neuromorphic computing substrates utilizing cultured neural networks maintained in controlled nutritional environments."
          </p>

          <p className="mb-6">
            The patent documentation, written in characteristically opaque federal prose, details bio-computing arrays that harness living brain tissue to perform computational tasks at speeds and efficiency levels that current silicon-based systems cannot achieve. These biological processing units, according to the technical specifications, operate optimally when supplied with specific neurochemical modulators—primarily dopamine and norepinephrine pathway agonists.
          </p>

          <div className="bg-blue-50 border border-blue-200 rounded-lg p-6 mb-6">
            <h4 className="text-lg font-bold text-blue-900 mb-3">Key Technical Specifications</h4>
            <ul className="list-disc list-inside text-blue-800 space-y-2">
              <li>Bio-computers maintain operational capacity for approximately 42 days per unit</li>
              <li>Cost-per-FLOP ratio roughly 10,000 times more favorable than NVIDIA H100 GPUs</li>
              <li>Energy consumption comparable to household refrigerator</li>
              <li>Processing power equivalent to entire server farms</li>
            </ul>
          </div>

          <blockquote className="border-l-4 border-red-600 pl-6 py-4 bg-gray-50 mb-6">
            <p className="text-lg italic text-gray-800">
              "The implications are staggering. While everyone's been focused on the GPU shortage and the astronomical costs of training large language models, someone's been developing a parallel pathway that could make silicon obsolete overnight."
            </p>
            <cite className="text-sm text-gray-600 mt-2 block">
              — Dr. Chen Wei-Ming, Former Intel Neuromorphic Computing Division
            </cite>
          </blockquote>

          <h3 className="text-2xl font-bold text-gray-900 mb-4 mt-8">Market Manipulation Evidence</h3>

          <p className="mb-6">
            Industry analysts have long noted NVIDIA's stranglehold on AI development, with their flagship GPU cards commanding prices exceeding $40,000 per unit and waiting lists stretching beyond 18 months. The computational requirements for state-of-the-art AI models have created an effective oligopoly, where only the largest technology corporations and nation-states can afford to participate in cutting-edge artificial intelligence research.
          </p>

          <p className="mb-6">
            The bio-computing alternative outlined in the federal patents would fundamentally alter this dynamic. The documents suggest that a single bio-computing array, maintained in a temperature-controlled enclosure roughly the size of a desktop computer, could match the processing power of entire server farms while consuming less energy than a household refrigerator.
          </p>

          <p className="mb-6">
            A former DEA chemist, speaking on condition of anonymity, confirmed that seized methamphetamine and diverted pharmaceutical amphetamines represent the most cost-effective source of the neurochemical precursors required for bio-computing applications.
          </p>

          <blockquote className="border-l-4 border-red-600 pl-6 py-4 bg-gray-50 mb-6">
            <p className="text-lg italic text-gray-800">
              "The purity levels we're seeing in seizures are far beyond what street dealers require. When you're confiscating 99% pure crystal methamphetamine in quantities measured in tons, and it's not being destroyed but transferred to 'federal research facilities,' you start to wonder about the ultimate destination."
            </p>
            <cite className="text-sm text-gray-600 mt-2 block">
              — Former DEA Chemist (Anonymous)
            </cite>
          </blockquote>

          <h3 className="text-2xl font-bold text-gray-900 mb-4 mt-8">Financial Trail</h3>

          <p className="mb-6">
            Financial records obtained through Freedom of Information Act requests show unusual budget allocations within the Department of Health and Human Services. The FDA's Office of Criminal Investigations has received funding increases of 340% over the past three fiscal years, while simultaneously establishing new "pharmaceutical asset management" divisions in twelve major cities.
          </p>

          <p className="mb-6">
            These facilities, according to architectural contractors familiar with the projects, feature specialized storage environments with precise temperature and humidity controls typically associated with biological research rather than evidence storage.
          </p>

          <blockquote className="border-l-4 border-red-600 pl-6 py-4 bg-gray-50 mb-6">
            <p className="text-lg italic text-gray-800">
              "It's the perfect regulatory capture scenario. The same agencies responsible for restricting access to these substances are positioned to become the exclusive suppliers for the next generation of computing technology."
            </p>
            <cite className="text-sm text-gray-600 mt-2 block">
              — Professor Janet Morrison, Georgetown University Public Policy Institute
            </cite>
          </blockquote>

          <h3 className="text-2xl font-bold text-gray-900 mb-4 mt-8">Global Implications</h3>

          <p className="mb-6">
            The strategic implications extend far beyond domestic technology policy. Recent analysis by the Center for Strategic and International Studies suggests that bio-computing capabilities could provide decisive advantages in cybersecurity, financial modeling, and autonomous weapons systems. A nation that controls the supply chain for bio-computing substrates would possess significant leverage over allies and adversaries alike.
          </p>

          <p className="mb-6">
            International pharmaceutical monitoring organizations have noted unusual patterns in amphetamine precursor chemical exports from the United States. Countries with established bio-technology research programs, including South Korea, Singapore, and Israel, have reportedly approached U.S. chemical suppliers seeking large-quantity purchases of dopamine pathway modulators, only to encounter unprecedented bureaucratic delays and regulatory requirements.
          </p>

          <blockquote className="border-l-4 border-red-600 pl-6 py-4 bg-gray-50 mb-6">
            <p className="text-lg italic text-gray-800">
              "The requests are getting denied or delayed indefinitely. Meanwhile, we're seeing American companies file patent applications for technologies that appear to require exactly these restricted compounds."
            </p>
            <cite className="text-sm text-gray-600 mt-2 block">
              — Dr. Kim Yong-su, Seoul National University
            </cite>
          </blockquote>

          <h3 className="text-2xl font-bold text-gray-900 mb-4 mt-8">Industry Response</h3>

          <p className="mb-6">
            The pharmaceutical industry has remained notably quiet about the unusual market dynamics. Major amphetamine manufacturers, including Teva Pharmaceuticals and Mallinckrodt, declined to comment on inventory management practices or government purchase agreements. However, quarterly earnings reports from these companies show significant revenue increases that cannot be attributed to prescription volume growth.
          </p>

          <p className="mb-6">
            Stock market analysts specializing in pharmaceutical sectors have noted unusual trading patterns in companies with amphetamine manufacturing capabilities. Share prices for these firms have outperformed market averages by substantial margins, despite flat or declining prescription demand for ADHD medications.
          </p>

          <blockquote className="border-l-4 border-red-600 pl-6 py-4 bg-gray-50 mb-6">
            <p className="text-lg italic text-gray-800">
              "The numbers don't match the narrative. You've got companies reporting record profits from amphetamine production while prescription volumes remain stable. The additional demand is coming from somewhere, and it's not traditional medical channels."
            </p>
            <cite className="text-sm text-gray-600 mt-2 block">
              — Robert Chang, Goldman Sachs Healthcare Sector Division
            </cite>
          </blockquote>

          <h3 className="text-2xl font-bold text-gray-900 mb-4 mt-8">Looking Forward</h3>

          <p className="mb-6">
            The timeline for full bio-computing deployment remains unclear, but patent filings suggest operational prototypes already exist. Military procurement records show unusual contract awards for "biological computing support services" with several defense contractors, including classifications that prevent public disclosure of project details.
          </p>

          <p className="mb-6">
            If the analysis proves accurate, the implications could reshape global technology competition within the next decade. Countries currently investing billions in traditional semiconductor manufacturing may find themselves pursuing obsolete technologies, while the United States maintains strategic control over the neurochemical supply chains required for next-generation computing.
          </p>

          <div className="bg-red-50 border border-red-200 rounded-lg p-6 mb-6">
            <h4 className="text-lg font-bold text-red-900 mb-3">Ongoing Investigation</h4>
            <p className="text-red-800">
              The investigation continues as researchers attempt to verify the extent of federal amphetamine accumulation and the current status of bio-computing research programs. Multiple federal agencies, including the DEA, FDA, and DARPA, have not responded to requests for comment regarding these allegations.
            </p>
          </div>

          <p className="mb-6">
            As the technology sector grapples with the limitations of silicon-based computing and the astronomical costs of AI development, the possibility that biological alternatives may already be under government control adds a new dimension to debates over technological sovereignty and market competition.
          </p>

          <p className="mb-6 font-medium">
            The story developing around federal amphetamine reserves may represent more than regulatory overreach—it could signal the emergence of an entirely new paradigm for both computing technology and geopolitical power projection in the digital age.
          </p>
        </div>

        {/* Article Footer */}
        <div className="border-t border-gray-200 pt-8 mt-12">
          <div className="flex items-center justify-between">
            <div className="text-sm text-gray-500">
              <p>Published: {new Date().toLocaleDateString('en-US', { 
                year: 'numeric', 
                month: 'long', 
                day: 'numeric',
                hour: '2-digit',
                minute: '2-digit'
              })}</p>
              <p>Category: Technology, Politics, Investigation</p>
            </div>
            <div className="flex items-center space-x-4">
              <button className="bg-blue-600 hover:bg-blue-700 text-white px-4 py-2 rounded-lg transition-colors">
                Share Article
              </button>
              <Link 
                href="/" 
                className="bg-gray-600 hover:bg-gray-700 text-white px-4 py-2 rounded-lg transition-colors"
              >
                Back to Home
              </Link>
            </div>
          </div>
        </div>
      </main>
    </div>
  );
}